Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry

Abstract

Background

Treatments for catastrophic antiphospholipid syndrome (CAPS) rose from recommendations and consensus of international experts based on case series or case reports. We aimed to evaluate the treatment scheme with the best cost-effectiveness ratio associated with lower mortality as a high-impact clinical benefit.

Methods

The CAPS Registry was used as our source of structured data on the different therapeutic strategies, their frequency, and their effectiveness (survival). Starting from around 50 different schemes, we identified those with a mortality of less than 33% within the 18 most frequently utilized. After applying the efficiency frontier method, we included two schemes to conduct a cost-effectiveness analysis from the Colombian healthcare sector perspective. Scheme 1 (Glucocorticoids + Anticoagulation + Anti-aggregation + Intravenous IgG immunoglobulin) and scheme 2 (Glucocorticoids + Anticoagulation + Anti-aggregation + Plasma exchange) were compared in terms of costs and survival. Deterministic and probabilistic sensitivity analyses (Monte Carlo simulation) were conducted to evaluate model robustness and uncertainty.

Results

Our analysis uses the information corresponding to 427 cases from the CAPS registry, the majority being women (68.8%), with a mean age of 45.7 years and bearing general mortality of 38.17% (female: 38.4%, male: 37.5%). Scheme 2 was the cost-effective strategy over scheme 1. The results were robust on discrete sensitivity analysis and probability sensitivity analysis (Monte Carlo simulation).

Conclusion

To our knowledge, this is the first economic evaluation focused on the treatment of CAPS. For the Colombian health system, schemes 1 and 2 have similar behavior; nevertheless, scheme 2 represents the best cost-effectiveness ratio. This treatment approach is highly susceptible to the allocation of resources by the system and beneficial in terms of health outcomes.

Keywords

Catastrophic antiphospholipid syndrome treatment economic evaluation rheumatology cost-effectiveness

Get full access to this article

View all access options for this article.

References

Asherson

. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19(4): 508–512.

Cervera

Piette

Font

, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019–1027. DOI: 10.1002/art.10187.

Cervera

Rodríguez-Pintó

Espinosa

. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun 2018; 92: 1–11. DOI: 10.1016/j.jaut.2018.05.007.

Bucciarelli

Espinosa

Cervera

, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54(8): 2568–2576. DOI: 10.1002/art.22018.

Cervera

Rodríguez-Pintó

Legault

Erkan

. 16th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Lupus 2020; 29(12): 1594–1600. DOI: 10.1177/0961203320951260.

Unlu

Erkan

. Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu Rev Med 2017; 68: 287–296. DOI: 10.1146/annurev-med-042915-102529.

Sanders

Maciejewski

Basu

. Overview of cost-effectiveness analysis. JAMA 2019; 321(14): 1400–1401. DOI: 10.1001/jama.2019.1265.

Brooke

Kaji

Itani

KMF

. Practical guide to cost-effectiveness analysis. JAMA Surg 2020; 155(3): 250–251. DOI: 10.1001/jamasurg.2019.4392.

Legault

Schunemann

Hillis

, et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost 2018; 16: 1656–1664. DOI: 10.1111/jth.1419210.1111/jth.14192.

10.

Instituto de Evaluación Tecnológica en Salud . Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogota, Colombia: Instituto de Evaluación Tecnológica en Salud; 2014.

11.

Cervera

Rodríguez-Pintó

Colafrancesco

, et al. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 2014; 13(7): 699–707. DOI: 10.1016/j.autrev.2014.03.002.

12.

Minsalud Colombia . Consulta Pública de Precios de Medicamentos en la Cadena de Comercialización (Minsalud Colombia. Public Consultation of Drug Prices in the Marketing Chain) [Internet]. Bogota, Colombia: Ministerio de Salud y Protección Social. Web.sispro.gov.co. 2019. Available from: https://web.sispro.gov.co/WebPublico/Consultas/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_2.aspx (Accessed January 2019)

13.

Banco de la República de Colombia . Tasa de cambio del peso colombiano (TRM). Bogota, Colombia: Banco de la República de Colombia. https://www.banrep.gov.co/es/estadisticas/trm (2020, (Accessed February 2020)

14.

Banco de la República de Colombia . PRODUCTO INTERNO BRUTO TOTAL Y POR HABITANTE (A Precios Corrientes) Año Base 2015. Bogota, Colombia: Banco de la República de Colombia. 2015, https://www.banrep.gov.co/es/estadisticas/producto-interno-bruto-pib

15.

Rodríguez-Pintó

Espinosa

Erkan

Shoenfeld

Cervera

CAPS Registry Project Group . The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford) 2018; 57(7): 1264–1270. DOI: 10.1093/rheumatology/key082.

16.

Berman

Rodríguez-Pintó

Cervera

, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12(11): 1085–1090. DOI: 10.1016/j.autrev.2013.05.004.

17.

Espinosa

Berman

Cervera

. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10(11): 664–668. DOI: 10.1016/j.autrev.2011.04.031.

18.

Ortel

Erkan

Kitchens

. How I treat catastrophic thrombotic syndromes. Blood 2015; 126(11): 1285–1293. DOI: 10.1182/blood-2014-09-551978.

19.

Rodríguez-Pintó

Lozano

Cid

Espinosa

Cervera

. Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med 2019; 48(11 Pt 2): 347–353. DOI: 10.1016/j.lpm.2019.10.003.

20.

Cervera

Bucciarelli

Plasín

, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry. J Autoimmun 2009; 32(3–4): 240–245. DOI: 10.1016/j.jaut.2009.02.008.

21.

Cervera

. CAPS Registrygistry. Lupus 2012; 21(7): 755–757. DOI: 10.1177/0961203312436866.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.67 MB